Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical India

Pfizer To Partner With Indian Firms To Research, Develop Cancer Drugs

This article was originally published in PharmAsia News

Executive Summary

Pfizer Inc. is said to be considering partnerships with Indian drug makers to research and develop cancer drugs as part of its concentration on treatments for emerging markets.

Pfizer Inc. is said to be considering partnerships with Indian drug makers to research and develop cancer drugs as part of its concentration on treatments for emerging markets. The firm’s head of Asia research said in an interview that cancer offers a great medical need for which significant scientific breakthroughs are being made. Vice President Richard Connell would not divulge the firm’s cancer-drug investment in India, but said Pfizer was drawn by India’s strength in bio-chemistry. (Click here for more)

“Pfizer Looking For Indian Companies To Partner In Treating Cancer Patients” – Economic Times (India) (2/18/12)
Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical India
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC080350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By